MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Abbott Laboratories

Затворен

СекторЗдравеопазване

123.73 2.37

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

123.53

Максимум

124.48

Ключови измерители

By Trading Economics

Приходи

-7.9B

1.3B

Продажби

-616M

10B

P/E

Средно за сектора

17.147

39.857

EPS

1.09

Дивидентна доходност

1.74

Марж на печалбата

12.792

Служители

114,000

EBITDA

-324M

2.7B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+17.79% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

1.74%

2.42%

Следващи печалби

15.10.2025 г.

Следваща дата на дивидент

15.08.2025 г.

Следваща дата на екс-дивидент

14.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.9B

230B

Предишно отваряне

121.36

Предишно затваряне

123.73

Настроения в новините

By Acuity

41%

59%

138 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Abbott Laboratories Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.07.2025 г., 12:10 ч. UTC

Печалби

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

16.04.2025 г., 16:21 ч. UTC

Печалби

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16.04.2025 г., 12:14 ч. UTC

Печалби

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

17.07.2025 г., 13:14 ч. UTC

Печалби

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17.07.2025 г., 12:16 ч. UTC

Печалби

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17.07.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17.07.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17.07.2025 г., 11:31 ч. UTC

Печалби

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Sales $11.14B >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Net $1.78B >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Adj EPS $1.26 >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q EPS $1.01 >ABT

17.07.2025 г., 09:08 ч. UTC

Горещи акции

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

1.07.2025 г., 18:41 ч. UTC

Придобивния, сливания и поглъщания

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

16.04.2025 г., 15:09 ч. UTC

Пазарно говорене

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16.04.2025 г., 14:17 ч. UTC

Печалби

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16.04.2025 г., 11:34 ч. UTC

Печалби

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16.04.2025 г., 11:33 ч. UTC

Печалби

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16.04.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16.04.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16.04.2025 г., 11:31 ч. UTC

Печалби

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Reaffirms Full-Yr Guidance

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 1Q Sales $10.36B >ABT

16.04.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 1Q Net $1.33B >ABT

Сравнение с други в отрасъла

Ценова промяна

Abbott Laboratories Прогноза

Ценова цел

By TipRanks

17.79% нагоре

12-месечна прогноза

Среден 145.67 USD  17.79%

Висок 159 USD

Нисък 135 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Abbott Laboratories през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

16

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

132.82 / 134.43Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

138 / 376 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.